Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock.
In related news, VP Robert A. Michael sold 6,699 shares of AbbVie stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $65.29, for a total transaction of $1,465,825.79. Focused Wealth Management has invested 0.04% in AbbVie Inc. (NYSE:ABBV) earned "Buy" rating by Goldman Sachs on Monday, March 7. Lombard Odier Asset Mngmt (Europe) Limited has 0.08% invested in AbbVie Inc. (NYSE:ABBV) for 86,027 shares.
AbbVie Inc. has its outstanding Shares of 1.6 Billion. About 131,162 shares traded. Mercer Advisers Incorporated holds 349 shares or 0.02% of its portfolio. Rhenman & Prtn Asset Mngmt holds 135,000 shares. Also, SVP Azita Saleki-Gerhardt sold 8,300 shares of AbbVie stock in a transaction that occurred on Monday, September 11th. Cincinnati Specialty Underwriters Co has invested 1.8% in AbbVie Inc. Jpmorgan Chase Com reported 0.06% of its portfolio in AbbVie Inc. South Texas Money Mngmt Ltd has 23,122 shares. Neuberger Berman Grp Incorporated Ltd Liability stated it has 929,934 shares. 45,800 shares were sold by ALBAN CARLOS, worth $3.21M on Wednesday, June 14.
Walleye Trading Llc who had been investing in Abbvie Inc (Put) for a number of months, seems to be less bullish one the $150.70 billion market cap company. The institutional investor held 161,243 shares of the commercial physical & biological resarch company at the end of 2017Q2, valued at $15.77 million, down from 173,058 at the end of the previous reported quarter. At high price movement business is attractive for near term view and is not recommended for traders with a long-term outlook especially since AbbVie Inc. stocks at 1.53 Beta shows lower correlation with the wider index. About 1.37M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since December 7, 2016 and is uptrending. It has underperformed by 6.07% the S&P500.
Walleye Trading Llc, which manages about $16.31B US Long portfolio, upped its stake in Anadarko Pete Corp (Put) (NYSE:APC) by 163,400 shares to 200,400 shares, valued at $9.09 million in 2017Q2, according to the filing. The firm's revenue for the quarter was up 8.8% compared to the same quarter last year. equities analysts predict that AbbVie will post 5.55 EPS for the current fiscal year. The company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.39 by $0.02. They expect $1.43 earnings per share, up 19.17 % or $0.23 from last year's $1.2 per share. For the most recent quarter, quick ratio was 2.60, current ratio was 2.70, LT Debt/Equity ratio was 0.41 and Total Debt/Equity ratio stands at 0.00, while Payout ratio is 23.60%. (NYSE:ABBV) news were published by: Nasdaq.com which released: "AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan" on December 06, 2017, also Washingtonpost.com with their article: "AbbVie Promises Too Much, Risks Delivering Too Little: Gadfly" published on November 06, 2017, Seekingalpha.com published: "AbbVie Raises Dividend 11%..." Franklin Parlapiano Turner & Welch LLC purchased a new position in shares of AbbVie in the first quarter worth about $108,000.
More recent ICON Public Limited Company (NASDAQ:ICLR) news were published by: Seekingalpha.com which released: "Icon PLC: A Hidden Gem In An Uncertain Industry" on August 29, 2017. "What Now?" on December 04, 2017, also Seekingalpha.com with their article: "AbbVie's risankizumab successful in fourth late-stage psoriasis study" published on December 04, 2017, Fool.com published: "The case for Johnson & Johnson" on November 21, 2017.
Sell side analysts plays vital role in buying and selling a stock where 3 analysts rated AbbVie Inc. Therefore 52% are positive. The stock now has an average rating of "Buy" and a consensus price target of $96.66. Abbvie Inc had 69 analyst reports since July 21, 2015 according to SRatingsIntel. Deutsche Bank maintained the stock with "Hold" rating in Monday, July 17 report. Finally, BMO Capital Markets reissued a "hold" rating and issued a $84.00 price target on shares of AbbVie in a research note on Tuesday, November 21st. The stock has "Outperform" rating by William Blair on Friday, February 5. Jefferies has "Buy" rating and $94.0 target. Jefferies upgraded AbbVie Inc. (NYSE:ABBV) rating on Friday, July 14. On Monday, October 31 the stock rating was downgraded by Credit Suisse to "Neutral". Deutsche Bank upgraded AbbVie Inc. (NYSE:ABBV) has "Market Perform" rating given on Friday, June 10 by BMO Capital Markets. Leerink Swann initiated the stock with "Mkt Perform" rating in Tuesday, October 18 report. On Friday, December 2 the stock rating was maintained by TD Securities with "Buy". The stock has "Buy" rating by Piper Jaffray on Friday, September 15.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.